| Liu, Zhuogang |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies |
|
|
| Active, not recruiting | 1 | 15 | RoW | 3D189 | 3D Medicines | Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome | 12/24 | 12/24 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
